Patents by Inventor Shigetaka MIMORI

Shigetaka MIMORI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220331419
    Abstract: Provided is a seasonal influenza vaccine having a higher efficacy than a split vaccine. A seasonal influenza vaccine which induces virus-specific antibodies in the nasal mucosa, comprises inactivated whole influenza virus particles as an active ingredient, and is to be administered intradermally at dose per administration of 15 ?g HA or more per strain as antigen.
    Type: Application
    Filed: September 2, 2020
    Publication date: October 20, 2022
    Applicant: DENKA COMPANY LIMITED
    Inventors: Ryotaro MITSUMATA, Asumi KANDA, Nagisa NAKATA, Shigetaka MIMORI
  • Patent number: 11299750
    Abstract: An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 12, 2022
    Assignees: DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Denka Company Limited, NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
    Inventors: Kei Haga, Akira Fujimoto, Reiko Todaka, Kazuhiko Katayama, Akira Nakanishi, Motohiro Miki, Sakari Sekine, Hiroshi Otsuka, Shigetaka Mimori
  • Publication number: 20190040415
    Abstract: An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.
    Type: Application
    Filed: February 1, 2017
    Publication date: February 7, 2019
    Applicants: JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, DENKA COMPANY LIMITED, NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY
    Inventors: Kei HAGA, Akira FUJIMOTO, Reiko TODAKA, Kazuhiko KATAYAMA, Akira NAKANISHI, Motohiro MIKI, Sakari SEKINE, Hiroshi OTSUKA, Shigetaka MIMORI